Fly News Breaks for January 16, 2020
Jan 16, 2020 | 09:05 EDT
Empire analyst Cathy Reese said there are still limited therapeutic choices for sickle cell disease patients and she believes Global Blood Therapeutics' Oxbryta has advantages that should allow the therapy to do well and gain "adequate reimbursement." Reese raised her price target for Global Blood Therapeutics shares to $98 from $85 and keeps a Buy rating on the stock.
News For GBT From the Last 2 Days
There are no results for your query GBT